| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/17/2008 | US20080089862 Serine protease inhibitor for prevention and treatment of cell proliferative, liver and inflammatory disorders |
| 04/17/2008 | US20080089861 Therapeutic agent comprising memantine and dimethyl fumarate for use in prevention and treatment of autoimmune and nervous system disorders |
| 04/17/2008 | US20080089860 Such as pentamidine; cytokines; interferons; granulocyte/macrophage colony stimulating factor; for treatment of diseases associated with PTPase activity, immune deficiency, cancer, infections, hepatitis B, and hepatitis C |
| 04/17/2008 | US20080089859 Administration of sleep restorative agents |
| 04/17/2008 | US20080089858 Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
| 04/17/2008 | US20080089845 optimizing therapeutic efficacy for treatment of anxiety, depression, pain, or a metabolic disorder by increasing or decreasing a dose of a fatty amide ( oleoylethanolamide or palmitoylethanolamide) hydrolase inhibitor according to a patient's fatty amide levels by administering a carbamate derivative |
| 04/17/2008 | DE102006050026A1 Use of lactic acid compounds as tumor necrosis factor-alpha blocker, e.g. for suppressing immune system, for prophylaxis and/or treatment of autoimmune diseases and/or inflammatory diseases, preferably rheumatoid arthritis, spondylitis |
| 04/17/2008 | DE102006048728A1 3-Amino-imidazo{1,2-a]pyridinderivate 3-amino-imidazo {1,2-a] pyridine |
| 04/17/2008 | DE102006048693A1 Inhibition der PDE2A Inhibition of PDE2A |
| 04/17/2008 | DE102006048530A1 Zubereitungen zur oralen Aufnahme (II) Preparations for oral administration (II) |
| 04/17/2008 | DE102006048042A1 Acylaminoimidazole und Acylaminothiazole Acylaminoimidazole and Acylaminothiazole |
| 04/17/2008 | DE102006021872B4 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel 4,5-diphenyl-pyrimidinyl-oxy or substituted mercapto carboxylic acids, process for their preparation and their use as medicaments |
| 04/17/2008 | CA2676133A1 Compositions for reducing nicotine withdrawal symptoms and/or tobacco usage |
| 04/17/2008 | CA2675518A1 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 04/17/2008 | CA2675511A1 N-aryl pyrazole compounds for use against diabetes |
| 04/17/2008 | CA2672931A1 Statin and omega-3 fatty acids for reduction of apo-b levels |
| 04/17/2008 | CA2672920A1 Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders |
| 04/17/2008 | CA2672919A1 Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels |
| 04/17/2008 | CA2672686A1 Pharmaceutical formulations |
| 04/17/2008 | CA2667071A1 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 04/17/2008 | CA2666658A1 Chymase inhibitors |
| 04/17/2008 | CA2666653A1 Polymorph b of n-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-n-methyl-acetamide |
| 04/17/2008 | CA2666563A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| 04/17/2008 | CA2666466A1 Complement inhibition for improved nerve regeneration |
| 04/17/2008 | CA2666440A1 Aqueous liquid preparation having improved intraocular gatifloxacin penetration |
| 04/17/2008 | CA2666396A1 Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| 04/17/2008 | CA2666373A1 Heterocyclic compounds useful as anabolic agents for livestock animals |
| 04/17/2008 | CA2666355A1 Inhibition of pde2a |
| 04/17/2008 | CA2666275A1 Cyclopropyl-piperazine compounds as calcium channel blockers |
| 04/17/2008 | CA2666184A1 The use of a dna damaging agent and a ligand for the treatment of cancer |
| 04/17/2008 | CA2666177A1 Acylaminoimidazoles and acylaminothiazoles |
| 04/17/2008 | CA2666170A1 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate |
| 04/17/2008 | CA2666146A1 Methods of inactivating viruses |
| 04/17/2008 | CA2666143A1 Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| 04/17/2008 | CA2666130A1 Kinase inhibitors |
| 04/17/2008 | CA2666084A1 1-naphthyl alkylpiperidine derivative |
| 04/17/2008 | CA2666058A1 Aqueous liquid preparation comprising gatifloxacin |
| 04/17/2008 | CA2665984A1 Superoxide dismutase mimetics for the treatment of oral mucositis |
| 04/17/2008 | CA2665931A1 Hydrobenzamide derivatives as inhibitors of hsp90 |
| 04/17/2008 | CA2665916A1 Novel curcumin and tetrahydrocurcumin derivatives |
| 04/17/2008 | CA2665764A1 Pharmaceutical anti-infective composition for inhalation |
| 04/17/2008 | CA2665692A1 Combination drug |
| 04/17/2008 | CA2665616A1 Effective delivery of cross-species a3 adenosine-receptor antagonists toreduce intraocular pressure |
| 04/17/2008 | CA2665611A1 Stabilized prostaglandin e composition |
| 04/17/2008 | CA2665605A1 New isocarbostyril alkaloid derivatives |
| 04/17/2008 | CA2665603A1 Medium supplement for virus production |
| 04/17/2008 | CA2665573A1 Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| 04/17/2008 | CA2665169A1 Purification of streptococcus pneumoniae type 3 polysaccharides |
| 04/17/2008 | CA2665127A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 04/17/2008 | CA2665075A1 High-purity large-scale preparation of stannsoporfin |
| 04/17/2008 | CA2665071A1 N-substituted-azacyclylamines as histamine-3 antagonists |
| 04/17/2008 | CA2665068A1 Methods for treating cancer with mva |
| 04/17/2008 | CA2665046A1 Vinylogous acids derivatives as chymase inhibitors |
| 04/17/2008 | CA2664934A1 Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin |
| 04/17/2008 | CA2664920A1 Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
| 04/17/2008 | CA2664915A1 Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent |
| 04/17/2008 | CA2664900A1 Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound |
| 04/17/2008 | CA2664569A1 Novel morphine derivatives and their uses for the treatment of pain and sexual dysfunction |
| 04/17/2008 | CA2664206A1 Meal replacement compositions comprising dha and weight control method |
| 04/17/2008 | CA2664147A1 Protein kinase inhibitors and methods for using thereof |
| 04/17/2008 | CA2664054A1 An antidepressant comprising a branched amino acid |
| 04/17/2008 | CA2664045A1 Novel method of treatment of male sub-fertility |
| 04/17/2008 | CA2663805A1 Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory |
| 04/17/2008 | CA2662643A1 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 04/17/2008 | CA2659923A1 Substituted pyrazinone derivatives for use as a medicine |
| 04/17/2008 | CA2652980A1 Robust sustained release formulations of oxymorphone |
| 04/17/2008 | CA2564263A1 Cardiac reperfusion methods and devices |
| 04/16/2008 | EP1911849A1 Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food |
| 04/16/2008 | EP1911836A1 Medium supplement for virus production |
| 04/16/2008 | EP1911762A1 Amino alcohols and their use as renin inhibitors |
| 04/16/2008 | EP1911761A1 Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions and the use thereof |
| 04/16/2008 | EP1911760A1 Xanthine oxidase inhibitor |
| 04/16/2008 | EP1911759A1 Azaindole derivative having pgd2 receptor antagonistic activity |
| 04/16/2008 | EP1911758A1 Phenyl piperidine derivatives for use as renin inhibitors |
| 04/16/2008 | EP1911757A2 Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors |
| 04/16/2008 | EP1911756A2 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| 04/16/2008 | EP1911755A1 Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| 04/16/2008 | EP1911754A1 Dipeptidyl peptidase inhibitors |
| 04/16/2008 | EP1911753A1 Spiro-cyclic compound |
| 04/16/2008 | EP1911749A1 New long-working Beta-2 agonists and their use as medicine |
| 04/16/2008 | EP1911747A1 Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators |
| 04/16/2008 | EP1911746A1 The substance having antioxidant, geroprotective and anti-ischemic activity and method for preparing thereof |
| 04/16/2008 | EP1911744A1 Tryptophan derivative and use thereof |
| 04/16/2008 | EP1911743A1 Cyclic amine compound |
| 04/16/2008 | EP1911740A1 Potassium channel modulators |
| 04/16/2008 | EP1911738A1 Phenoxyalkanoic acid compound |
| 04/16/2008 | EP1911494A2 Use of oligosaccharides to stimulate beta-endorphin production |
| 04/16/2008 | EP1911471A1 Agent for visualizing vitreous body |
| 04/16/2008 | EP1911463A1 Weight management system for obese animals |
| 04/16/2008 | EP1911462A2 Compositions comprising a sterol absorption inhibitor |
| 04/16/2008 | EP1911455A1 Topical vaginal pharmaceutical compositions |
| 04/16/2008 | EP1911454A1 A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vaginal |
| 04/16/2008 | EP1911453A2 Immunemodulating oligosaccharides |
| 04/16/2008 | EP1911452A1 Silicon-derivates for PET-Imaging |
| 04/16/2008 | EP1911451A1 Protein-kinase CK2 inhibitors and their therapeutic applications |
| 04/16/2008 | EP1911450A1 Use of cymipristones for treating aids |
| 04/16/2008 | EP1911449A1 Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof |
| 04/16/2008 | EP1911448A2 Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| 04/16/2008 | EP1911447A1 Eye drop preparation comprising xanthan gum and terpenoid |
| 04/16/2008 | EP1911446A2 The use of PPAR-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired plasticity |